Le @LAGEPP est fier de vous informer que Hatem FESSI professeur émérite fait partie des chercheurs les plus cités d’après le classement annuel 2022 “Highly Cited Researchers” de Clarivate. https://clarivate.com/highly-cited-researchers/?action=clv_hcr_members_filter&clv-paged=1&clv-category=&clv-institution=Universite%20Claude%20Bernard%20Lyon%201&clv-region=&clv-name= Félicitations à Hatem !
Keywords: Nanocarriers, nucleic acid, physico-chemical characterization, oral administration, in vivo studies Aim of the thesis: The aim of the thesis project is to develop a multifunctional therapeutic system that will enable oral delivery of oligonucleotides for the treatment of inflammatory bowel pathologies. A translation approach to develop innovative hydrogel-doped nanoparticle platform and to evaluate their...
The postdoc will be part of the ANR project HyDNano working closely with different partners from industry and academic research groups. The aim of the project is to optimize and characterize novel nanomedicines for the oral or systemic delivery of genetic material or small drugs. Toutes les infos Post doc_LAGEPP
Supervisors: Dr. Giovanna Lollo Keywords: Nanocarriers, nucleic acid, physico–chemical characterization, oral administration, in vivo studies Starting date: January 2022 (12–18 months) Laboratory: The LAGEPP (https://lagepp.univ–lyon1.fr/en/home/) is a research laboratory of the University Lyon 1 and the French national Institute for scientific research (CNRS UMR 5007). It develops pluridisciplinary research in chemical engineering, pharmaceutical engineering and...
Titre : Treatment of peritoneal carcinomatosis using nanomedicines loaded with oxaliplatin derivatives administered via pressurized nebulization Approche thérapeutique de la carcinose péritonéale en utilisant des NANOmedicines à base de dérivé d’oxaliplatin administrés par NEBulisation pressurisée Financement : SATT Ouest Valorisation Durée : 03-2021 / 06-2023 Resumé: Le projet NanoNeb vise à développer une nouvelle approche thérapeutique dans la...
